Ianhez M, et al. - Investigators examined the clinical, histological, and immunohistochemical impact of oral and topical retinoid (10 mg/day oral isotretinoin and 0.05% tretinoin cream) for treatment of actinic keratoses (AKs) and field cancerization on the face and upper limbs of immunocompetent patients (aged 50–75 years) as well as its influence on the quality of life, safety, and tolerability. They observed a decrease in the number of AKs (around 28%), the thickness of stratum corneum, and expression of p53 and Bax with both the treatments. Both treatments enhanced the quality of life and were well tolerated with minimal side effects.